BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28719656)

  • 1. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.
    Messaritakis I; Politaki E; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Kallergi G; Souglakos J; Georgoulias V
    PLoS One; 2017; 12(7):e0181211. PubMed ID: 28719656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib.
    Messaritakis I; Politaki E; Koinis F; Stoltidis D; Apostolaki S; Plataki M; Dermitzaki EK; Georgoulias V; Kotsakis A
    Sci Rep; 2018 Feb; 8(1):2238. PubMed ID: 29396560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment.
    Messaritakis I; Nikolaou M; Politaki E; Koinis F; Lagoudaki E; Koutsopoulos A; Georgoulia N; Georgoulias V; Kotsakis A
    Lung Cancer; 2018 Oct; 124():270-278. PubMed ID: 30268472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
    Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
    Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
    Messaritakis I; Politaki E; Plataki M; Karavassilis V; Kentepozidis N; Koinis F; Samantas E; Georgoulias V; Kotsakis A
    Lung Cancer; 2017 Feb; 104():16-23. PubMed ID: 28212995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).
    Messaritakis I; Stoltidis D; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Politaki E; Apostolaki S; Souglakos J; Georgoulias V
    Sci Rep; 2017 Mar; 7():45351. PubMed ID: 28349943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients.
    Shi WL; Li J; Du YJ; Zhu WF; Wu Y; Hu YM; Chen YC
    Med Oncol; 2013 Dec; 30(4):755. PubMed ID: 24178178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
    Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
    J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.
    Hosokawa M; Kenmotsu H; Koh Y; Yoshino T; Yoshikawa T; Naito T; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Shukuya T; Ono A; Akamatsu H; Watanabe R; Ono S; Mori K; Kanbara H; Yamaguchi K; Tanaka T; Matsunaga T; Yamamoto N
    PLoS One; 2013; 8(6):e67466. PubMed ID: 23840710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
    Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F
    Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of circulating tumor cells in patients with small cell lung cancer.
    Naito T; Tanaka F; Ono A; Yoneda K; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Kenmotsu H; Shukuya T; Kaira K; Koh Y; Endo M; Hasegawa S; Yamamoto N
    J Thorac Oncol; 2012 Mar; 7(3):512-9. PubMed ID: 22258473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
    Hou JM; Greystoke A; Lancashire L; Cummings J; Ward T; Board R; Amir E; Hughes S; Krebs M; Hughes A; Ranson M; Lorigan P; Dive C; Blackhall FH
    Am J Pathol; 2009 Aug; 175(2):808-16. PubMed ID: 19628770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.
    Spiliotaki M; Mavroudis D; Kapranou K; Markomanolaki H; Kallergi G; Koinis F; Kalbakis K; Georgoulias V; Agelaki S
    Breast Cancer Res; 2014 Nov; 16(6):485. PubMed ID: 25432416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
    Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
    Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
    J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
    Milaki G; Messaritakis I; Koinis F; Kotsakis A; Apostolaki S; Dermitzaki EK; Perraki M; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):101-108. PubMed ID: 28523597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer.
    Normanno N; Rossi A; Morabito A; Signoriello S; Bevilacqua S; Di Maio M; Costanzo R; De Luca A; Montanino A; Gridelli C; Rocco G; Perrone F; Gallo C
    Lung Cancer; 2014 Aug; 85(2):314-9. PubMed ID: 24882383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer.
    Wang Y; Liu Y; Zhang L; Tong L; Gao Y; Hu F; Lin PP; Li B; Zhang T
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):2911-2920. PubMed ID: 31646374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.